Logo
x

Search

Subscribe Now

Formosa

Formosa Entered into a License Agreement with Eyenovia to Commercialize APP13007 for Inflammation and Pain Following Ocular Surgery

Formosa Entered into a License Agreement with Eyenovia to Commercialize APP13007 for Inflammation and Pain Following Ocular Surger...

  • August 16, 2023
Formosa and AimMax Report Results of CPN-301 in the P-III Trial for the Treatment of Inflammation and Pain after Cataract Surgery

Formosa and AimMax Report Results of CPN-301 in the P-III Trial for the Treatment of Inflammation and Pain after Cataract Surgery

  • May 13, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.